Monday, April 15, 2019
Knight Therapeutics Inc., Canada's leading specialty pharmaceutical company, is pleased to announce the introduction of PROBUPHINE ™ , a new opioid dependence treatment, for patients across the country.
Approved by Health Canada in April 2018, PROBUPHINE ™ is the only subcutaneous implant designed to deliver buprenorphine continuously for 6 months after the first treatment. The insertion and removal of the product is done by a health professional who has completed and completed the practical training of the PROBUPHINE ™ program .
Knight holds the exclusive distribution rights to PROBUPHINE ™ in Canada pursuant to a licensing agreement with Titan Pharmaceuticals, Inc. (NASDAQ: TTNP).
"Probuphine offers a new and unique option to treat opioid abuse, which overcomes the barriers of daily monitoring and multiple clinic and pharmacy visits," said Dr. Ken Lee, London's Chief Medical Officer. Director of the Rapid Access Addiction Medicine Clinic (RAAM) ".
Jonathan Ross Goodman, Knight's CEO, added, "We are delighted to see Maritime and BC health professionals taking our hands-on training and offering access to Probuphine through the country. Opioid addiction in Canada continues to be a devastating public health scourge and we are proud to be at the forefront of improving the lives of patients who need it. "
Update of the Company
Knight welcomes the growing support from shareholders and analysts as the Company continues its commitment to the 2019 Annual Meeting of Shareholders, to be held on May 7, 2019. More recently, it has welcomed the support National Bank of Canada Financial Markets, which organized a series of meetings with investors last week. Knight discussed its vision and plans to expand its product portfolio, its approach to expanding its geographic reach in Canada and around the world, and the intention of management after the AGM , explore strategies to return capital to shareholders by focusing on the repurchase of shares rather than dividends.
About PROBUPHINE ™
PROBUPHINE ™ is the only subcutaneous implant designed to deliver buprenorphine continuously for 6 months after a single treatment. PROBUPHINE ™ was developed using ProNeura ™ , a continuous drug delivery system developed by Titan Pharmaceuticals Inc. and consisting of a small solid implant consisting of a mixture of ethylene vinyl acetate (CAV / E) and buprenorphine. Four subcutaneous implants are inserted by a health care professional into the inside of the upper arm of the patient during an in-office procedure, and are similarly removed at the end of the treatment period. PROBUPHINE ™should only be inserted and removed by a health professional who has completed and successfully completed the PROBUPHINE ™ practice training . Knight Therapeutics Inc. obtained Health Canada's approval of PROBUPHINE ™ in April 2018, the first buprenorphine implant for long-term maintenance treatment of opioid dependence.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or licensing innovative pharmaceutical distribution rights for the distinctive Canadian and international markets. Knight's shares trade on the TSX under the symbol "GUD". For more information about Knight Therapeutics Inc., visit their website at www.gud-knight.com or www.sedar.com .
This document may contain forward-looking statements and forecasts for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. Knight Therapeutics Inc. believes that the assumptions upon which these forward-looking statements are based are believed to be reasonable as of the date they are made, but it warns the reader that these assumptions about future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may prove to be incorrect. Factors and risks that could cause actual results to differ materially from expected results are discussed in Knight Therapeutics Inc.'s annual report. and in the annual notice of Knight Therapeutics Inc. for the year ended December 31, 2018. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.
Knight Therapeutics Investor Information Inc.
President and Chief Financial Officer
Tel. : 514-678-8930
Fax. : 514-481-4116
Senior Vice President, Communications Strategy
Direct Line: 416-867-2333